TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients should be voluntary to the trial and provide with signed informed consent.~2. Male or female patients, age:18-70 years old~3. Confirmed by histology of thoracic esophageal squamous cell carcinoma without metastasis and diagnosed as boundary resectable by Multidisciplinary consultation, including cT4 and/or bulky lymphadenopathy that may invade nearby organs(such as the great vessels, trachea and heart, etc.)~4. Measurable or unmeasurable lesions according the RECIST 1.1 criteria.~5. No previous chemotherapy or radiotherapy.~6. Life expectancy ≥ 3 months.~7. ECOG PS 0-1.~8. Blood routine within 7 days：Hb ≥9g/L，NE ≥1.5×109/L，PLT ≥100×109/L；~9. Hepatic and renal function：TB \<1.5 UNL， Cr\< 1.5× UNL， AST / ALT \< 2.5× UNL， ALP \< 5.0 × UNL。~10. No severe complications such as active digestive tract hemorrhage, perforation, jaundice, gastrointestinal obstruction, non-cancerous fever \> 38 ℃~11. Fertile patients should take effective contraceptive measures.~12. Patients should have good compliance and cooperate with the evaluation of efficacy and adverse events and follow-ups according to the research plan.~Exclusion Criteria:~1. Cervical esophageal carcinoma.~2. Known severe hypersensitivity to drugs in the regimen.~3. Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment(with the exception of nonmelanoma skin cancer or cervical carcinoma in situ).~4. Evidence of serious heart disease, including recorded history of congestive heart-failure, uncontrolled serious arrhythmia, angina that needs treatment of drugs, clinical diagnosed cardiac valve disease, history of serious myocardial infarction and intractable hypertension.~5. Evidence of chronic diarrhea(≥4 times/day) or renal dysfunction.~6. Evidence of active infection or active epidemic disease.~7. Psychiatric illness that would prevent the patient from giving informed consent~8. Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Paclitaxel+Cisplatin+5fluorouracil (Type: EXPERIMENTAL): Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Subjects must satisfy the following criteria to be enrolled in the study.~1. Subjects must have documented diagnosis of multiple myeloma and have measurable disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24 hours).~5. Subjects must have had at least 1 prior antimyeloma regimen including lenalidomide and documented progression as per the International Myeloma Working Group uniform response criteria (Durie, 2006) during or after the last antimyeloma regimen. Induction therapy followed by Autologous Stem Cell Transplant and consolidation/ maintenance will be considered as one regimen.~6. Subjects must have an impaired renal function with an estimated Glomerular Filtrate Rate of \< 45 mL/min/1.73 m2 according to the modification of diet in renal disease equation.~1. Impaired renal function must be due to multiple myeloma which needs to be confirmed by kidney biopsy.~2. Subjects may have acute myeloma related renal failure or chronic myeloma related renal failure; they may also have been treated with dialysis before, including dialysis with high cut off membranes.~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment~1. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.~2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.~3. Renal insufficiency due to other reasons than multiple myeloma or due to hypocalcaemia only.~4. Prior history of malignancies, other than MM, unless the subject has been free of the disease for ≥ 5 years; exceptions include the following:~   1. Basal or squamous cell carcinoma of the skin~  2. Carcinoma in situ of the cervix or breast~  3. Incidental histological finding of prostate cancer (Tumour lymphNode Metastasis stage of T1a or T1b)~6. Previous therapy with pomalidomide. 7. Hypersensitivity to thalidomide, lenalidomide, or dexamethasone (this includes ≥ Grade 3 rash during prior thalidomide or lenalidomide therapy).~10. Subjects who are planning for or who are eligible for stem cell transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide and low dose Dexamethasone (Type: EXPERIMENTAL): Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (\> 75 years old)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 80~2. Diagnosis of moderately to severely active Crohn's disease (CD)~3. CD involvement of the ileum and/or colon~4. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents, within protocol-specified parameters:~   1. Immunomodulators~  2. Tumor necrosis factor-alpha (TNFα) antagonists~  3. Corticosteroids~5. May be receiving a therapeutic dose of conventional therapies for irritable bowel disease (IBD) defined by the protocol~Exclusion Criteria~1. Evidence of abdominal abscess at the initial screening visit, other than a minimum of 10 aphthous ulcerations involving a minimum of 10 contiguous cm of intestine~2. Extensive colonic resection, subtotal or total colectomy~3. History of \>3 small bowel resections or diagnosis of short bowel syndrome~4. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine~5. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol~6. Chronic hepatitis B or C infection~7. Active or latent tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
- Placebo (Type: PLACEBO_COMPARATOR): In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose BAYA1040_Nifedipine: a Dose-comparative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years or older~* Japanese male or female~* Outpatient with essential hypertension~* Patients whose sitting diastolic blood pressure (DBP) is 90 mmHg or more despite more than 4 weeks of treatment with antihypertensive drug~Exclusion Criteria:~* Sitting diastolic blood pressure (DBP) is 110 mmHg or more or sitting systolic blood pressure (SBP) is 180 mmHg or more~* Patients with secondary hypertension or hypertensive emergency

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects whose parents /legal representative have given written informed consent.~* Both gender~* Subject up to 36 months of age.~* Subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months~Exclusion Criteria:~* Subjects whose parents/legal representative have not given written informed consent.~* Subjects out of aged range~* Subjects with malignancies or chemotherapy treatment~* Subjects included in another clinical trial in the last 12 months.~* Subject in immunosuppressive or immunostimulatory treatment~* Subjects who have received iv gamma globulin in the past 12 months.~* Subjects diagnosed with candidiasis or fungal recurrent infections.~* Subjects diagnosed with malabsorption syndrome~* Subjects with clinical allergy to common aeroallergens in the geographical area.~* Subjects with hepatitis virus infections, HIV and tuberculosis

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
- Biological vaccine (Type: EXPERIMENTAL): The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically proven NAFLD or NASH based on a biopsy performed during the preceding 18 months fulfilling the following criteria:~  * At least 15% of hepatocytes showing steatosis,with Fibrosis of not more than stage 3, with at most bridging fibrosis.~Patients with a NAFLD activity score 0-2 will be considered to have NAFLD. Biopsies with an activity score of 3 or more will be considered NASH.~* Triglycerides concentration in the liver of 6% or more as measured by NMRS.~* At least two elevated serum ALT levels in the previous six months, with latest test within 2 months of trial.~* Normal or only slightly impaired synthetic liver function (serum albumin \>3.5gm%, INR 0.8-1.3)~* Male or female aged 18-75 years.~* Negative pregnancy test at study entry for females of child bearing potential.~* Females of child bearing potential practicing reliable contraception throughout the study period.~* Signature of the written informed consent~Exclusion Criteria:~* Evidence of cirrhosis on liver biopsy.~* Evidence of fibrosis of more than stage 3 on liver biopsy.~* Patient with liver disease due to acute or chronic hepatitis A, B,C, HIV, and all other liver diseases affecting liver function. Patients with cysts, hemangiomas, or similar abnormalities, are accepted.~* BMI \> 35 or \>130 kg body weight~* Any other concomitant, significant: metabolic, infectious, inflammatory, neoplastic, or other non-liver disease.~* Various concomitant diseases requiring chronic steroid administration.~* Use of warfarin, metformin, thiaglitazones, insulin or current steroid therapy of more than 3 days.~* Use of other investigational agents \< 30 days prior to the study.~* Pregnancy~* Daily alcohol intake \> 10gm/day.~* Patients with symptoms of significant mental illness. Inability to cooperate or communicate with the investigator, who are unlikely to comply with the study requirements, or who are unable to give informed consent.~* Performance status: WHO performance status ≥4.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- high dose (Type: EXPERIMENTAL): Aramchol 300 mg daily (high dose)
- low dose (Type: EXPERIMENTAL): 100 mg daily (low dose)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 - 39 years inclusive~* Provide written informed consent to participate~* Healthy participants without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality~  o As determined by medical history, physical exam, laboratory screening~* Body Mass Index 18-35 kg/m2, inclusive, at screening~Exclusion Criteria:~* Any medical condition that in the judgement of the investigator would make subject participation in the study unsafe.~* Having cancer or received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), which are allowed unless located at the vaccination site.~* Impaired immune responsiveness (of any cause), including diabetes mellitus.~* Receipt or plan to receive a non-study vaccine within 30 days prior to vaccination or 60 days after vaccination.~* Receipt of any influenza vaccine in previous 24 months and/or planned receipt of influenza vaccine for the duration of the study.~* Diagnosed influenza infection in the previous 24 months prior to screening.~* Diagnosed COVID infection via medical personnel or at home test within the past 60 days prior to screening~* Allergy to influenza vaccine or components, or history of severe local or systemic reaction to any vaccination.~* History of anaphylactic type reaction to injected vaccines~* History of or current allergy to latex~* History of Guillain-Barré Syndrome.~* Positive test result for hepatitis B surface antigen (HBsAg,), hepatitis C virus antibody (HBcAb), or human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.~* History of chronic obstructive pulmonary disease or history of other lung disease.~* History of severe allergic reactions to eggs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- 15 μg of the H1 influenza antigen (Type: ACTIVE_COMPARATOR): None
- 7.5 μg of the H1 influenza antigen (Type: ACTIVE_COMPARATOR): None
- Placebo (no antigen) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Deep BLock on Intraoperative Surgical Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with renal or prostatic disease who are will undergo an elective laparoscopic renal surgical procedure or laparoscopic prostatectomy;~* ASA class I-III~* \> 18 years of age;~* Ability to give oral and written informed consent~Exclusion Criteria:~* Known or suspected neuromuscular disorders impairing neuromuscular function;~* Allergies to muscle relaxants, anesthetics or narcotics;~* A (family) history of malignant hyperthermia;~* Patients who have a contraindication for neostigmine administration;~* Women who are or may be pregnant or are currently breast feeding;~* Renal insufficiency, as defined by serum creatinine x 2 of normal, or urine output \< 0.5 ml/kg/h for at least 6 h. When available, other indices will be taken into account as well such as glomerular filtration rate \< 60 ml/h and proteinuria (a ratio of 30 mg albumin to 1 g of creatinine).~* Previous retroperitoneal surgery at the site of the current surgery.~* Body mass index \> 35 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep surgical block (Type: EXPERIMENTAL): Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
- Moderate/normal surgical block (Type: ACTIVE_COMPARATOR): A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* BMI 18 to 30 kg/m2~* Females postmenopausal or surgically sterile~Exclusion Criteria:~* Any uncontrolled or active major systemic disease including, but not limited to: acromegaly (with or without pituitary surgery or radiation therapy), cardiac, pulmonary, gastrointestinal, metabolic, urogenital, neurological, immunological, psychiatric, or neoplastic disorder with metastatic potential~* History or presence of malignancy within the past 5 years. Subjects who have been successfully treated (for 3 months or longer) with no recurrence of basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix may be enrolled.~* Use of any investigational drug within the past 60 days or 5 half-lives, whichever is longer~* Have a medically significant abnormality observed during screening or the admission physical examination or in any other baseline measurements~* Use of any prior medication without approval of the investigator within 14 days prior to admission~* Tested positive at screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV-Ab) or has a history of a positive result~* History of alcohol or substance abuse in the past 6 months~* Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this Phase 1 study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CRN00808 Oral Solution (Type: EXPERIMENTAL): CRN00808 oral solution, single-dose
- CRN00808 Oral Capsule (Type: EXPERIMENTAL): CRN00808 oral capsule, single-dose and multiple-doses
- Placebo Oral Solution (Type: PLACEBO_COMPARATOR): Placebo oral solution, single-dose
- Placebo Oral Capsule (Type: PLACEBO_COMPARATOR): Placebo oral capsule, single-dose and multiple doses
- Midazolam Oral Solution (Type: OTHER): Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete